Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
Phase 3
Completed
- Conditions
- Impetigo
- Registration Number
- NCT00133848
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
Not provided
Exclusion Criteria
- Any signs and symptoms of systemic infection.
- Any serious underlying disease that could be imminently life threatening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment.
- Secondary Outcome Measures
Name Time Method Clinical response of impetigo at follow up visit. Impetigo lesion area at end of therapy and follow up visits.
Trial Locations
- Locations (1)
GSK Investigational Site
🇵🇪Lima, Peru